Women’s and Health Practitioner's Perspectives, Experiences and Preferences of Intrauterine Contraceptive Devices

None listed

Alyra Biotech Pty Ltd is an Australian-owned biopharma company that wishes to develop an optimal intrauterine contraceptive device (IUCD) for young women with period or pelvic pain. We wish to determine the priorities of two end-user groups: women who may choose an IUCD for contraception or other health concerns, and Health Practitioners who advise women regarding the risks and benefits of IUCD use. Intrauterine devices are chosen as a form of contraception by 14% of women worldwide, with use of levonogestrel-releasing intrauterine devices increasing globally. However, some women experience increased pelvic pain in the 3-6 months after insertion. We wish to research the experiences, perspectives and preferences of both end-user groups to assist us in planning an optimal device for women with pain. The views and experiences of our end-user groups will guide our product development. Finally, to ensure that our product is commercially feasible, we wish to determine the cost premium that users, or prescribers, of the device would accept for such a device. The primary objectives of this study are: 1. To determine the market potential for an intrauterine device that reduced pain in the first 3 months post-insertion by 50%. 2. To determine whether these women whether these women would be prepared to pay a price premium for such a device sufficient to justify device commercialisation. 3. To determine whether Health Practitioners who offer intrauterine contraceptive devices would prefer a device that reduced pain by 50% in the first 3 months post-insertion. 4. To investigate whether Health Practitioners believe their patients with dysmenorrhea or Chronic Pelvic Pain would pay a price premium for an IUCD that reduced post insertion pain compared with their patients who are pain free.

No related papers found yet.